US states may end aid for Part D "donut hole"

28 May 2009

Six US states are reported to be debating cuts or the outright abolition of financial assistance to seniors who reach the coverage gap in the  Medicare Part D prescription drug benefit (the "donut hole;"  Marketletters passim). According to the Associated Press, a total of 16  states provide some form of support for affected people. In the current  fiscal year, the coverage gap takes effect when total spending on  prescription medicines reaches $2,100 and is less than the "catastrophic  coverage" threshold of $4,350.

In the northeastern USA, both Rhode Island and Vermont's state Governors  have proposed to scrap "donut hole" assistance, while neighboring  Massachusetts has made cuts to its program. In contrast, Connecticut and  New York have considered and rejected any reduction in support. Further  south, the legislature in South Carolina has a plan under consideration  to end subsidies for patients reaching the coverage gap.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight